Siddha Herbal Preparation- MV Kashayam for the Treatment, Control and Management of COVID-19 - A Clinical Study

Authors

  • S. P. Malarkannan Department of Rural Development Science, Arul Anandar College, Karumathur, Madurai, Tamil Nadu, India.
  • P. Dharumarajan Department of Indian Medicine and Homeopathy, Government Hospital, Aruppukottai, Virudhunagar Dist, Tamil Nadu, India.
  • M. K. Hariyogesh Medical School Foundation, Daevo Medical School Foundation Inc, Poblacion District, Davo City, 8000 Davo del Sur, Philippines.

DOI:

https://doi.org/10.9734/bpi/capr/v9/4158E

Keywords:

COVID, siddha preparation, MV kashayam, treatment

Abstract

A composition is prepared for the treatment and management of certain types of bacterial and viral diseases like coronavirus (COVID-19), H1N1, ZIKA virus, HIV, Hantavirus, Ebola virus etc. comprising ingredients of desired parts of Solanum xanthocarpum, Tinospora cordifolia, Zingiber officinalis, Tragia involucrata, Clerodendrum serratum, Cyperus rotundus, Piper longum, Andrographis paniculata, Mollugo cerviana, and Costus speciosus in the required quantity. The ingredients are boiled under the mild flame for a definite period and reduced its volume to a specific quantity. The supernatant liquid hence obtained is filtered and used as a "Kashayam". The Kashayam is antiviral (COVID 19), antibacterial, antiasthmatic, immunostimulant, anti-inflammatory, antipyretic, hepatoprotective, anti-diarrheal, anti-ulcer, antioxidant, thrombolytic agent, anticancer, anti-poisonous effect, laxative, cardiotonic activity, CNS depressant, antihypertensive, and anti-epileptic activity against diseases of zoonotic importance or communicable diseases that result in infections such as Coronavirus (COVID-19),  H1N1, ZIKA virus, HIV, Hantavirus, Ebola virus, etc. and provides clarity of mind.

Published

2022-11-10

How to Cite

S. P. Malarkannan, P. Dharumarajan, & M. K. Hariyogesh. (2022). Siddha Herbal Preparation- MV Kashayam for the Treatment, Control and Management of COVID-19 - A Clinical Study. Challenges and Advances in Pharmaceutical Research Vol. 9, 32–53. https://doi.org/10.9734/bpi/capr/v9/4158E